Company Description

The Vaccine Company, an Eli Lilly company, is developing proprietary In Vivo Nanoparticle (IVN) technologies designed to enable the antigen display known to elicit durable immune responses associated with virus-like particle vaccines, while avoiding the manufacturing burden of traditional VLP production.